FEMSelect, a privately held women-led company revolutionizing women's pelvic health, today announced its expansion into the incontinence market through a strategic partnership with Elidah, developer ...

Patients who receive an Altaviva device return home with therapy activated. Medtronic says this marks a first among ...

Low-dose vaginal estrogens, available in various applications such as creams, tablets, inserts, and rings, are the mainstay of GSM treatment.

DUBLIN and CHICAGO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a company focused on delivering next generation oral and IV antibiotics to treat infections ...

March On! Festival unites activists and storytellers to address health equity and challenge historic roots of inequity in the ...

Analysts said Altaviva is an attractive option compared to rival products, informing their belief that Medtronic can ...

Medtronic's Altaviva wins FDA approval as a minimally invasive implant for urge urinary incontinence, offering long-lasting ...

Medtronic has received FDA approval for a new implant aimed at improving bladder control, with a small device placed near the ...

(HealthDay News) — Receiving remote behavioral urinary incontinence (UI) treatment through either a mobile health app or video visit improves symptoms among women veterans, according to a study ...

Implantation of the device is minimally invasive, requiring no sedation or imaging, and is conducted near the ankle.

Medtronic (NYSE: MDT) today reported the first patient treated with its Altaviva neuromodulation device for urge urinary incontinence.

The FDA gave premarket approval to the first medical device for the treatment of women with symptomatic moderate-to-severe intrauterine adhesions, known as Asherman syndrome, maker Womed announced on ...